MENLO PARK, Calif., Sept. 10, 2019 /PRNewswire/ — Ablacon, Inc. (www.ablacon.com), an Ajax Health-funded company, announced today the release of an updated version of its Ablamap technology under the company’s existing CE Mark. The new update includes an enhanced physician experience and user interface, along with significantly faster processing times leading to improved procedural efficiency. It will be rolled out to all current centers and will be used in the upcoming FLOW-AF clinical study, which will study the technology in patients with persistent atrial fibrillation (AFib).
Posts
Ablamap® System and Ablacath is FDA 510(k) cleared for use in the United States.
Caution: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use for information on Indications, Contraindications, Warnings, Precautions and Adverse events.
Copyright © 2023 Ablacon, Inc.
Caution: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use for information on Indications, Contraindications, Warnings, Precautions and Adverse events.
Copyright © 2023 Ablacon, Inc.